![]() | |
![]() | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| License data | |
| Routes of administration | Intravenous |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | Nil |
| Metabolism | Nil |
| Elimination half-life | 80 to 120 minutes |
| Excretion | Renal |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H34GdN5O10 |
| Molar mass | 661.77 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| | |
Gadoversetamide is a gadolinium-based MRI contrast agent, particularly for imaging of the brain, spine and liver.[1][2] It is marketed under the trade name OptiMARK.
Notes
- ↑ "Gadoversetamide Drug Information". Drugs.com. 2000-03-20. Archived from the original on 2007-10-10. Retrieved 2007-03-23.
- ↑ Cheng KT (10 December 2007). "Gadoversetamide: Gd-DTPA-BMEA". Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). PMID 20641436.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

